STAT Expert Advantage is a partnership between Slingshot Insights and STAT News. This product is no longer being offered. We appreciate your interest.
Upcoming Projects
Executed Projects
-
Part 2 - Preparing for the FDA Panel on Aducanumab: Discussing the Briefing Documents with a Neurologist before the Ad-com
Ticker: BIIB
Executed On: Nov 05, 2020 at 03:00 PM EST
Included with STAT Expert Advantage -
Preparing for the FDA Panel on Aducanumab: What might panel members, the agency, and physicians be thinking about Biogen's application days before the Ad-com?
Ticker: BIIB
Executed On: Oct 28, 2020 at 01:00 PM EDT
Included with STAT Expert Advantage -
A Deep Dive Into Phenylketonuria (PKU) - Exploring New Approaches by BioMarin, Homology, Rubius, and Moderna
Tickers: BMRN, RUBY, MRNA, FIXX
Executed On: Aug 28, 2020 at 02:15 PM EDT
Included with STAT Expert Advantage -
A Look at the Breast Cancer Landscape: An Expert's Take on the Newly Approved Daiichi Sankyo Drug, ENHERTU, SGEN's tucatinib, & the Role of IO therapy
Tickers: D4S.F, SGEN
Executed On: Jul 30, 2020 at 04:00 PM EDT
Included with STAT Expert Advantage -
Looking into the Chronic Heart Failure Market with a review of: Myokardia’s Mavacamten program, Amgen & Cytokinetics' omecamtiv mecarbil as they continue development with the GALACTIC-HF trial, and Novartis' Entresto.
Tickers: MYOK, NVS, AMGN, CYTK
Executed On: Jul 10, 2020 at 02:00 PM EDT
Included with STAT Expert Advantage -
Exploring gene therapy treatments in the hemophilia space including those from BioMarin, Spark Therapeutics, and UniQure
Tickers: BMRN, QURE, ONCE
Executed On: May 20, 2020 at 11:00 AM EDT
Included with STAT Expert Advantage -
How will companies, patients, and the FDA navigate the impact of COVID-19 on Clinical Trials? A conversation with the former Director of the FDA Orphan Drug Division.
Ticker: IBB
Executed On: Apr 16, 2020 at 12:00 PM EDT
Included with STAT Expert Advantage -
Branching into the world of health tech, join STAT Reporters and a cardiologist for a call about the Apple watch HEARTLINE trial run in partnership with Johnson & Johnson
Tickers: AAPL, JNJ
Executed On: Mar 20, 2020 at 11:00 AM EDT
Included with STAT Expert Advantage -
Discussing Biogen's Regulatory Chances for Aducanumab in Alzheimer's with an Alzheimer's Expert.
Ticker: BIIB
Executed On: Feb 27, 2020 at 10:00 AM EST
Included with STAT Expert Advantage -
After a positive FDA panel for Aimmune's and FDA decision looming, we will discuss the commercial potential of Palforzia. NOTE: Call will have a proprietary survey, run by SI, of high volume pediatric allergists/immunologists available.
Tickers: AIMT, DBVT
Executed On: Jan 29, 2020 at 02:00 PM EST
Included with STAT Expert Advantage -
Reviewing Novel Mechanisms in Depression: SAGE-217 in MDD, Axsome Therapeutics' AXS-05, and Recently Approved Esketamine From JNJ.
Tickers: SAGE, JNJ, AXSM
Executed On: Nov 25, 2019 at 02:00 PM EST
Included with STAT Expert Advantage -
Preparing For the Panel: Discussing the Amarin's Vascepa Data Before Next Month's Unexpected Advisory Committee. (Including a survey of 25 cardiologists on their utilization pre and post REDUCE-IT!)
Ticker: AMRN
Executed On: Nov 05, 2019 at 10:00 AM EST
Included with STAT Expert Advantage -
Peanut allergy treatments: What’s next for the field?
Tickers: AIMT, DBVT
Executed On: Aug 28, 2019 at 11:00 AM EDT
Included with STAT Expert Advantage -
Discussing the Sickle Cell Landscape and Emerging Treatment Options Including Voxelotor, Rivipansel, and LentiGlobin.
Tickers: GBT, PFE, GLYC, BLUE
Executed On: Jul 23, 2019 at 02:30 PM EDT
Included with STAT Expert Advantage -
Taking a Look at the Changing Landscape for Spinal Muscular Atrophy After AAN 2019 and Pending FDA Decision On Zolgensma's Approval
Tickers: NVS, BIIB, RHHBY
Executed On: May 22, 2019 at 10:00 AM EDT
Included with STAT Expert Advantage -
Digging into Amarin's REDUCE-IT, including new data presented during the American College of Cardiology’s scientific session
Ticker: AMRN
Executed On: Mar 20, 2019 at 12:00 PM EDT
Included with STAT Expert Advantage -
Preparing for Amarin's REDUCE-IT Data Read-Out for Vascepa in Patients with Elevated Cardiovascular Risk
Ticker: AMRN
Executed On: Jul 17, 2018 at 10:30 AM EDT
Included with STAT Expert Advantage
